Steven Wolf, MD
Neurology · New York, NYNPI 1487645693
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $299,719 of the $428,299 with a category attached, or 70.0%. It is spread thinly across 53 manufacturers, the largest accounting for just 13.4%. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,348 payments — averaging $317.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$57K
- UCB, Inc.$53K
- Neurelis, Inc.$47K
- Greenwich Biosciences, Inc.$45K
- Jazz Pharmaceuticals Inc.$42K
- SK Life Science, Inc.$26K
- plus $158K from 47 others
Across 148 payments — averaging $4394.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$217K
- Neurelis, Inc.$147K
- Takeda Pharmaceuticals U.S.A., Inc.$106K
- Livanova USA, Inc.$85K
- Neuropace, Inc.$48K
- SK Life Science, Inc.$35K
- plus $13K from 1 others
What the payments were for
- Consulting fees$72,52617%
- Speaking & faculty fees$299,71970%
- Travel & lodging$24,7316%
- Food & beverage$31,2287%
- Education$350%
- Gifts$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$84,182
- Fintepla$66,209
- VALTOCO$45,596
- Fycompa$43,273
- ACTHAR$35,362
- SYMPAZAN$19,114
- XCOPRI$18,125
- ZTALMY$17,718
- APTIOM$13,968
- OXTELLAR XR$11,360
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$8,388
- Neuroblate$7,561
- Banzel$6,222
- Cenobamate$5,325
- RNS System$4,625
- Brineura$2,000
- VNS - Sentiva$1,700
- RNS Neurostimulator Kit$1,345
- VNS Therapy$1,067
- AFINITOR$247
How this compares
$428,299 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 47 | $307,830 |
| IngrezzaValbenazine Tosylate | 16 | $194,181 |
| AptiomEslicarbazepine Acetate | 56 | $94,684 |
| BriviactBrivaracetam | 40 | $68,864 |
| FycompaPerampanel | 34 | $46,829 |
| NayzilamMidazolam | 33 | $40,639 |
| VimpatLacosamide | 23 | $30,900 |
| TrileptalOxcarbazepine | 17 | $29,779 |
| Carbamazepine ErCarbamazepine | 149 | $26,140 |
| Lacosamide | 183 | $24,366 |
| Levetiracetam | 507 | $23,227 |
| Divalproex Sodium | 295 | $23,072 |
| KeppraLevetiracetam | 12 | $21,180 |
| Keppra XrLevetiracetam | 12 | $20,199 |
| ValtocoDiazepam | 14 | $17,369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $24 | $194,18116 claims |
| UCB, Inc.Briviact, Nayzilam, Vimpat | $52,874 | $140,40496 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $14,587 | $94,68456 claims |
| Eisai Inc.Fycompa | $57,363 | $46,82934 claims |
| Neurelis, Inc.Valtoco | $47,201 | $17,36914 claims |
| Upsher-smith Laboratories LLCTopiramate | $166 | $1,347130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
- Aaron MillerNew York$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.